What happened with FEMY today?
No read yet
Uses news and trading volume to explain the day’s move and how it relates to the market.
Stop guessing. Get the call, a three-month target price, the best and worst cases, and a source for every claim.
Femasys sells products that gynecologists and infertility specialists use to treat patients seeking pregnancy. Its FDA-cleared FemaSeed device delivers sperm into a fallopian tube, while FemSperm prepares sperm for use in doctors’ offices. The company sells FemaSeed through its own U.S. sales team and expects FemaSeed, FemVue and FemSperm to provide most of its U.S. revenue. Providers buy the products and bill patients for treatment, often directly because fertility insurance coverage varies; insurers may pay when coverage applies.
The company also sells FemBloc, a system for permanent birth control. FemBloc has European CE marking, but Femasys cannot market or sell it in the United States until it receives FDA approval. Its planned U.S. business would sell the system to gynecology practices performing permanent contraception in their offices.
Current product revenue remains limited. Sales depend on doctors and patients adopting these procedures and on patients’ ability to pay or obtain insurance coverage. Femasys has funded operations mainly through stock sales and convertible debt, rather than product revenue, and needs additional capital to complete FemBloc’s U.S. development and support European commercialization.
The risk section is the longest, dullest part of the filing. This keeps only what can really hurt you: where it hits, how hard, when it plays out.
Every company claims an edge. Each one is checked against hard numbers like margins and returns: which hold, and which line gives way first.
Femasys’s fertility sales hinge on winning adoption against established IUI and IVF alternatives, including IUI devices from Cook Medical and Cooper Surgical, neither shown in this list.
INVO Fertility competes for the fertility-treatment spending Femasys targets: it sells INVOcell devices to fertility clinics and earns fees from patients at its own clinics offering IVF and fertilization inside the woman’s body. Watch INVO’s clinic-service revenue for demand for these alternatives to Femasys’s insemination products, which it sells to gynecologists and infertility specialists.
Utah Medical Products offers an established surgical alternative to Femasys’s FemBloc permanent contraception system: its Femcare business sells Filshie clips for closing the fallopian tubes. If FemBloc wins U.S. approval, Femasys will need gynecology practices to choose its in-office system over alternatives such as this surgery.
Utah Medical Products Inc earningsUTMD
Utah Medical Products’ Femcare sales will show whether providers and patients are still choosing Filshie clips, a surgical alternative in the permanent-contraception market Femasys’s FemBloc hopes to enter.
Watch sales in Utah Medical Products’ Femcare business, not as a proxy for FemBloc sales. Stronger sales would show continued demand for an established surgical option, meaning FemBloc would still need to persuade practices to use its in-office system if approved. Weaker sales would point to softer demand for this type of permanent contraception, but would not prove FemBloc would see the same result.
Femasys Inc. earningsThis company
Femasys’s report will show whether product sales are growing enough to cover more of the costs of making and selling them, easing its reliance on outside funding.
Read product sales alongside the cost of sales, then check operating cash use. Sales growing faster than costs while cash use narrows would show commercialization contributing more; if sales remain small and costs and cash use stay high, product revenue is not yet carrying the business and funding pressure remains.
INVO Fertility, Inc. earningsIVF
INVO Fertility’s clinic-service revenue will show whether patients are still paying for fertility treatment, providing demand context for Femasys’s products sold to fertility specialists.
Watch INVO Fertility’s clinic-service revenue, not as a stand-in for Femasys product sales. Growth would show patients continuing to pay for a different fertility-treatment route, supporting the broader treatment-spending backdrop; a decline would indicate pressure on spending through that route. Either way, it is context, not direct proof of demand for Femasys’s insemination products.
